Screener
Axsome Therapeutics AXSM Total Revenue
Total Revenue at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Revenues: | ||
| Product sales, net | $189,400 | $120,358 |
| Royalty revenue and milestone revenue | 1,803 | 1,105 |
| Total revenues | 191,203 | 121,463 |
| Operating expenses: | ||
| Cost of revenue (excluding amortization and depreciation) | 14,725 | 9,789 |
| Research and development | 52,677 | 44,785 |
| Selling, general and administrative | 184,996 | 120,787 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's total revenue?
- Axsome Therapeutics (AXSM) reported total revenue of $191.2M in Q1 2026.
- How has Axsome Therapeutics's total revenue changed year-over-year?
- Axsome Therapeutics's total revenue increased by 57.4% year-over-year, from $121.46M to $191.2M.
- What is the long-term trend for Axsome Therapeutics's total revenue?
- Over 3 years (2022 to 2025), Axsome Therapeutics's total revenue has grown at a 133.7% compound annual growth rate (CAGR), from $50.04M to $638.5M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Axsome Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude